 The FDA has approved a new use of bevacizumab Avastin as part of secondline combination therapy for metastatic colorectal cancer the drugs manufacturer announced In patients who have failed a combination of bevacizumab and chemotherapy with fluoropyrimidine agents such as fluorouracil along with irinotecan Camptosar or oxaliplatin Eloxatin bevacizumab may be continued as other irinotecan or oxaliplatincontaining regimens are tried as salvage therapy Genentech said The FDA had not previously approved this particular use of bevacizumab in secondline treatment of metastatic colorectal cancer according to a company statement Most patients diagnosed with metastatic colorectal cancer now receive bevacizumab along with chemotherapy as initial treatment Genentech asserted The new approval was based on a phase III trial showing a  percent reduction in mortality when bevacizumab was used in both first and secondline regimens compared with chemotherapy alone in the salvage regimen Median overall survival was  months with the bevacizumabcontaining salvage therapy compared with  months with standard treatment Median progressionfree survival was  months versus  months according to Genentech Adverse events were similar to those seen in other trials of bevacizumab in metastatic colorectal cancer Previously use of bevacizumab for colorectal cancer was approved only as initial treatment of metastatic disease in combination with FUbased chemotherapies It is not indicated for adjuvant therapy Genentech noted Source 